Our case distinguishes itself from others in the literature; however, we present a previously undescribed POLE variant mutation in the exonuclease proofreading domain in a subject with an MSS but ultra-mutated colon cancer treated with pembrolizumab. Here, POLE is linked to colonic neoplasm.